Gastrin I (human): Advanced Applications in Gastrointestinal Physiology and Organoid Research

Introduction

The precise regulation of gastric acid secretion is pivotal for maintaining gastrointestinal homeostasis and understanding the pathogenesis of related disorders. Gastrin I (human), an endogenous peptide hormone, plays a central role as both a gastric acid secretion regulator and a CCK2 receptor agonist. Its ability to activate receptor-mediated signal transduction and modulate proton pump activity has made it a cornerstone in gastric acid secretion pathway research. While previous studies have focused on its actions in traditional cell-based and animal models, the advent of advanced in vitro systems such as human pluripotent stem cell-derived intestinal organoids enables unprecedented exploration of gastrointestinal physiology and drug interaction studies in a human-relevant context.

Biochemical Properties and Mechanisms of Gastrin I (human)

Gastrin I (human), with a molecular weight of 2098.22 Da and CAS number 10047-33-3, is a peptide hormone secreted primarily by G cells in the gastric antrum. Its biological activity is mediated through high-affinity binding to the cholecystokinin B (CCK2) receptor, a G-protein-coupled receptor predominantly expressed on gastric parietal cells and enterochromaffin-like (ECL) cells. Upon binding, Gastrin I (human) initiates a cascade of intracellular signaling events, particularly the phospholipase C/inositol trisphosphate (PLC/IP3) pathway, resulting in increased cytosolic calcium and subsequent activation of the gastric proton pump (H⁺/K⁺-ATPase). This receptor-mediated signal transduction ultimately enhances gastric acid secretion, underpinning its critical role in digestive physiology and its frequent use as a tool in proton pump activation and CCK2 receptor signaling research.

Gastrin I (human) in Gastrointestinal Physiology Studies

As a potent CCK2 receptor agonist, Gastrin I (human) is indispensable for dissecting the molecular mechanisms of gastric acid secretion. Its application in vitro enables researchers to directly stimulate parietal cells and ECL cells, facilitating quantitative and mechanistic studies of acid secretion, histamine release, and receptor pharmacodynamics. High-purity preparations of Gastrin I (human) (≥98% by HPLC and mass spectrometry) ensure reproducibility and reliability in experimental outcomes, particularly when investigating the downstream consequences of CCK2 receptor signaling and the modulation of the gastric acid secretion pathway in health and disease. Experimental protocols typically utilize the peptide dissolved in DMSO at concentrations ≥21 mg/mL, with careful storage (-20°C, desiccated) to preserve biological activity.

Integration with Human Intestinal Organoid Models

The emergence of human pluripotent stem cell (hPSC)-derived intestinal organoids marks a paradigm shift in gastrointestinal disorder research and pharmacokinetic evaluation. Unlike traditional cell lines or animal models, organoids recapitulate the architecture and functional complexity of the native human intestine, comprising multiple differentiated epithelial cell types. Recent work by Saito et al. (European Journal of Cell Biology, 2025) demonstrates that hiPSC-derived organoids exhibit robust self-renewal, differentiation into mature intestinal epithelial cells (IECs), and functional expression of drug transporters and cytochrome P450 enzymes. These attributes render them highly suitable for modeling human-specific aspects of absorption, metabolism, and drug–peptide interactions.

In this advanced context, Gastrin I (human) offers several unique research advantages:

• Functional Maturation: Application of Gastrin I (human) to intestinal organoids can be leveraged to study the maturation and responsiveness of enteroendocrine and parietal-like cells within the organoid system, providing insights into human gastric acid secretion regulation and epithelial cell signaling not possible in animal models.
• Pharmacokinetic Modulation: The peptide can be used to probe the effects of gastric acid secretion on drug solubility, absorption, and transporter activity within organoid-based pharmacokinetic assays, addressing challenges highlighted by Saito et al. related to species differences and limitations of Caco-2 cell models.
• Modeling Disease and Therapeutic Interventions: By incorporating Gastrin I (human) into disease-relevant organoid models, researchers can dissect the pathological mechanisms of hypergastrinemia, atrophic gastritis, and peptic ulcer disease, as well as evaluate candidate therapeutics targeting the CCK2 receptor or proton pump pathways.

Advanced Experimental Strategies: Practical Considerations

Designing experiments with Gastrin I (human) in organoid and traditional cell systems requires attention to its solubility and stability profile. The peptide is insoluble in water and ethanol but dissolves readily in DMSO, allowing for high-concentration stock solutions. However, due to limited long-term stability of solutions, aliquots should be prepared and used promptly to ensure experimental consistency. Rigorous quality control by HPLC and mass spectrometry is essential to avoid confounding effects from peptide impurities, especially in sensitive signal transduction studies involving CCK2 receptor signaling. When integrating with organoid models, titration of Gastrin I (human) should be performed to mimic physiological or pathophysiological concentrations, with parallel analysis of downstream functional readouts such as acid secretion, cell proliferation, and gene expression changes.

Expanding Horizons: Gastrin I (human) in Gastrointestinal Disorder Research

Gastrin I (human) facilitates not only fundamental studies of gastric acid regulation but also translational research into gastrointestinal disorders. In organoid-based systems, it is possible to induce or recapitulate disease phenotypes associated with dysregulated CCK2 receptor signaling or altered proton pump activation. For example, hyperstimulation of CCK2 receptors with exogenous Gastrin I (human) can model conditions such as Zollinger-Ellison syndrome, while antagonism or genetic manipulation can illuminate resistance mechanisms to acid-suppressive therapies. Furthermore, organoid models enable high-throughput screening of novel CCK2 receptor modulators, providing a bridge between basic discovery and preclinical evaluation.

These sophisticated approaches align with the recommendations of Saito et al. (2025), who emphasize the need for more predictive, human-relevant platforms in drug absorption and metabolism research. By integrating Gastrin I (human) into these systems, investigators can generate data with higher translational value, reduce reliance on animal models, and accelerate the development of targeted therapies for gastrointestinal diseases.

Future Perspectives and Technical Opportunities

The convergence of peptide biochemistry and stem cell biology opens new avenues for exploring gastrointestinal physiology. Future research may focus on:

• Organoid-on-a-chip platforms: Incorporating Gastrin I (human) into microfluidic systems to simulate dynamic gastric acid secretion and drug absorption under flow conditions.
• Single-cell transcriptomics: Profiling cellular responses to Gastrin I (human) at single-cell resolution within heterogeneous organoid cultures to elucidate cell-type-specific signaling networks.
• Personalized medicine: Utilizing patient-derived iPSC organoids and tailored Gastrin I (human) stimulation protocols to study individual variability in gastric physiology and drug response.

With its robust biochemical properties and established role as a gastric acid secretion regulator, Gastrin I (human) remains an essential reagent for both fundamental and translational studies at the forefront of gastrointestinal research.

Conclusion

Gastrin I (human) serves as a critical experimental tool for elucidating the complexities of gastric acid secretion, CCK2 receptor signaling, and proton pump activation. Its integration with emerging human-relevant models—particularly stem cell-derived intestinal organoids—enables more physiologically meaningful studies of gastrointestinal function, drug metabolism, and disease pathogenesis. This approach not only addresses the shortcomings of conventional models, as highlighted by Saito et al. (2025), but also expands the possibilities for innovative research into gastrointestinal disorders and therapeutic strategies.

In contrast to the existing article, "Gastrin I (human): A Versatile Tool for Gastric Acid Secr...", which primarily discusses the peptide’s role in classical acid secretion assays and receptor studies, this review highlights the integration of Gastrin I (human) with advanced organoid models and stem-cell derived systems. By focusing on cutting-edge in vitro methodologies and translational applications, this article offers novel perspectives and practical guidance for leveraging Gastrin I (human) in contemporary gastrointestinal physiology studies and pharmacokinetic research.